Significance of hypoxia-inducible factor‑1α expression with atrial fibrosis in rats induced with isoproterenol

Su,Fangju; Zhang,Weize; Chen,Yongqing; Ma,Ling; Zhang,Hanping; Wang,Fei

doi:10.3892/etm.2014.1989

Significance of hypoxia-inducible factor‑1α expression with atrial fibrosis in rats induced with isoproterenol

Authors:
- Fangju Su
- Weize Zhang
- Yongqing Chen
- Ling Ma
- Hanping Zhang
- Fei Wang
View Affiliations

Affiliations: Department of Cardiology, Lanzhou General Hospital, People's Liberation Army, Lanzhou, Gansu 730050, P.R. China
Published online on: September 24, 2014 https://doi.org/10.3892/etm.2014.1989
Pages: 1677-1682

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Atrial interstitial fibrosis plays a dual role in inducing and maintaining atrial fibrillation (AF). Hypoxia‑inducible factor‑1α (HIF‑1α) has been reported as closely associated with renal, liver and pulmonary fibrosis diseases. However, whether HIF‑1α is involved in myocardial fibrosis, and the associations between HIF‑1α, transforming growth factor‑β1 (TGF‑β1) and matrix metalloproteinase‑9 (MMP‑9) remain unknown. Therefore, this area warrants studying for the significance of AF diagnosis and treatment. The present study investigated the expression of HIF‑1α in atrial fibrosis and its possible mechanism in isoproterenol (ISO)‑induced rats. The three groups of rats; control, ISO and ISO plus sirolimus [also known as rapamycin (Rapa)], were treated for 15 days and sacrificed to remove the myocardial tissues. The expression levels of HIF‑1α, TGF‑β1 and MMP‑9 and their associations with atrial fibrosis were examined through histomorphology and protein and mRNA levels. The protein and mRNA levels of HIF‑1α, TGF‑β1 and MMP‑9 in the ISO group were increased markedly (P<0.01) compared with the control group, while those in the Rapa group were clearly decreased (P<0.01) compared with the ISO group. The protein and mRNA levels of HIF‑1α, TGF‑β1 and MMP‑9 were positively correlated (P<0.01) with atrial fibrosis (collagen volume fraction index), as were the HIF‑1α, TGF‑β1 and MMP‑9 mRNA levels (P<0.01) and the mRNA levels between MMP‑9 and TGF‑β1 (P<0.01). During the process of atrial fibrosis in ISO‑induced rats, HIF‑1α promotes the expression of TGF‑β1 and MMP‑9 protein, and thus is involved in in atrial fibrosis.

View Figures

View References

1	Meiltz A, Zimmermann M, Urban P and Bloch A: Association of Cardiologists of the Canton of Geneva: Atrial fibrillation management by practice cardiologists: a prospective survey on the adherence to guidelines in the real world. Europace. 10:674–680. 2008. View Article : Google Scholar : PubMed/NCBI
2	Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ and Wolf PA: Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 271:840–844. 1994. View Article : Google Scholar : PubMed/NCBI
3	Pan CH, Lin JL, Lai LP, Chen CL, Stephen Huang SK and Lin CS: Downregulation of angiotensin converting enzyme II is associated with pacing-induced sustained atrial fibrillation. FEBS Lett. 581:526–534. 2007. View Article : Google Scholar : PubMed/NCBI
4	Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA and Maseri A: Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 96:1180–1184. 1997. View Article : Google Scholar : PubMed/NCBI
5	Everett TH IV, Li H, Mangrum JM, et al: Electrical, morphological, and ultrastructural remodeling and reverse remodeling in a canine model of chronic atrial fibrillation. Circulation. 102:1454–1460. 2000. View Article : Google Scholar : PubMed/NCBI
6	Li D, Shinagawa K, Pang L, et al: Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation. 104:2608–2614. 2001. View Article : Google Scholar
7	Wang Z, Tang L, Zhu Q, et al: Hypoxia-inducible factor-1α contributes to the profibrotic action of angiotensin II in renal medullary interstitial cells. Kidney Int. 79:300–310. 2011.
8	Zhang YG, Li YG, Liu BG, et al: Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol. Acta Pharmacol Sin. 28:36–43. 2007. View Article : Google Scholar : PubMed/NCBI
9	Hudson CC, Liu M, Chiang GG, et al: Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol. 22:7004–7014. 2002. View Article : Google Scholar : PubMed/NCBI
10	Dong Y, Huang YF, Wang LQ and Chen B: Experimental study on the effects of rapamycin in prevention of rat corneal allograft rejection. Zhonghua Yan Ke Za Zhi. 41:930–935. 2005.(In Chinese).
11	Matsushita K, Wu Y, Okamoto Y, Pratt RE and Dzau VJ: Local renin angiotensin expression regulates human mesenchymal stem cell differentiation to adipocytes. Hypertension. 48:1095–1102. 2006. View Article : Google Scholar : PubMed/NCBI
12	Zhang WZ, Wang ZG, Chen YQ, et al: Effects of valsartan and U0126 on atrial fibrosis and connexin40 remodeling in rats. Zhonghua Xin Xue Guan Bing Za Zhi. 39:1129–1134. 2011.(In Chinese).
13	Fine LG and Norman JT: Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int. 74:867–872. 2008. View Article : Google Scholar : PubMed/NCBI
14	Copple BL, Kaska S and Wentling C: Hypoxia-inducible factor activation in myeloid cells contributes to the development of liver fibrosis in cholestatic mice. J Pharmacol Exp Ther. 341:307–316. 2012. View Article : Google Scholar : PubMed/NCBI
15	Rosmorduc O and Housset C: Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease. Semin Liver Dis. 30:258–270. 2010. View Article : Google Scholar : PubMed/NCBI
16	Ueno M, Maeno T, Nomura M, et al: Hypoxia-inducible factor-1α mediates TGF-β-induced PAI-1 production in alveolar macrophages in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 300:L740–L752. 2011.
17	Haase VH: Hypoxia-inducible factor signaling in the development of kidney fibrosis. Fibrogenesis Tissue Repair. 5(Suppl 1): S162012.PubMed/NCBI
18	Thijssen VL, van der Velden HM, van Ankeren EP, et al: Analysis of altered gene expression during sustained atrial fibrillation in the goat. Cardiovasc Res. 54:427–437. 2002. View Article : Google Scholar : PubMed/NCBI
19	Gramley F, Lorenzen J, Jedamzik B, et al: Atrial fibrillation is associated with cardiac hypoxia. Cardiovasc Pathol. 19:102–111. 2010. View Article : Google Scholar : PubMed/NCBI
20	Rosenkranz S, Flesch M, Amann K, et al: Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am J Physiol Heart Circ Physiol. 283:H1253–H1262. 2002.PubMed/NCBI
21	Lim JY, Park SJ, Hwang HY, et al: TGF-beta1 induces cardiac hypertrophic responses via PKC-dependent ATF-2 activation. J Mol Cell Cardiol. 39:627–636. 2005. View Article : Google Scholar : PubMed/NCBI
22	Mihout F, Shweke N, Bigé N, et al: Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-β1 synthesis. J Pathol. 223:37–45. 2011.PubMed/NCBI
23	Higgins DF, Kimura K, Bernhardt WM, et al: Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest. 117:3810–3820. 2007.PubMed/NCBI
24	Ogi H, Nakano Y, Niida S, et al: Is structural remodeling of fibrillated atria the consequence of tissue hypoxia? Circ J. 74:1815–1821. 2010. View Article : Google Scholar : PubMed/NCBI
25	Isobe K, Kuba K, Maejima Y, et al: Inhibition of endostatin/collagen XVIII deteriorates left ventricular remodeling and heart failure in rat myocardial infarction model. Circ J. 74:109–119. 2010. View Article : Google Scholar : PubMed/NCBI
26	Xu J, Cui G, Esmailian F, et al: Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation. 109:363–368. 2004. View Article : Google Scholar : PubMed/NCBI
27	Nakano Y, Niida S, Dote K, et al: Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation. J Am Coll Cardiol. 43:818–825. 2004. View Article : Google Scholar : PubMed/NCBI
28	Santibañez JF, Guerrero J, Quintanilla M, Fabra A and Martínez J: Transforming growth factor-beta1 modulates matrix metalloproteinase-9 production through the Ras/MAPK signaling pathway in transformed keratinocytes. Biochem Biophys Res Commun. 296:267–273. 2002.PubMed/NCBI
29	Zhang BB, Cai WM, Weng HL, et al: Diagnostic value of platelet derived growth factor-BB, transforming growth factor-beta1, matrix metalloproteinase-1, and tissue inhibitor of matrix metalloproteinase-1 in serum and peripheral blood mononuclear cells for hepatic fibrosis. World J Gastroenterol. 9:2490–2496. 2003.